📊 NAMSW Key Takeaways
Is NAMSW a Good Investment? Thesis Analysis
NewAmsterdam Pharma exhibits catastrophic operational deterioration with 50.6% YoY revenue collapse to $22.5M and a -$225.7M operating loss generating -1002.9% operating margin. The company is burning $148M annually in negative free cash flow, making current operations fundamentally unsustainable despite a $490M cash cushion. The magnitude of losses relative to revenue indicates severe business model dysfunction requiring dramatic operational restructuring or successful pipeline catalysts to justify investment.
Why Buy NAMSW? Key Strengths
- Strong cash position of $490M provides 3-4 year runway even at current burn rate
- Minimal debt exposure with 0.00x debt-to-equity ratio and $85.9M total liabilities
- Excellent liquidity metrics with 7.88x current and quick ratios provide financial flexibility
NAMSW Investment Risks to Consider
- Revenue collapse of 50.6% YoY to $22.5M indicates severe product, market, or competitive challenges
- Operating loss of $225.7M on minimal revenue demonstrates fundamental business model breakdown
- Negative operating cash flow of -$147.8M shows unsustainable cash burn that will deplete reserves despite strong balance sheet
Key Metrics to Watch
- Revenue stabilization and pathway to positive growth
- Operating cash flow trends and rate of cash reserve depletion
- Pipeline clinical trial results and regulatory approvals driving potential business recovery
NAMSW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.88x current ratio provides a solid financial cushion.
NAMSW Profitability Ratios
NAMSW vs Healthcare Sector
How NewAmsterdam Pharma Co N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NAMSW Overvalued or Undervalued?
Based on fundamental analysis, NewAmsterdam Pharma Co N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NAMSW Balance Sheet & Liquidity
NAMSW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NewAmsterdam Pharma Co N.V.'s revenue has declined by 56% over the 5-year period, indicating business contraction. The most recent EPS of $-2.15 indicates the company is currently unprofitable.
NAMSW Growth Metrics (YoY)
NAMSW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $348.0K | -$16.6M | $-0.18 |
| Q2 2025 | $2.3M | -$17.4M | $-0.15 |
| Q1 2025 | $1.4M | -$39.5M | $-0.34 |
| Q3 2024 | $2.9M | -$16.6M | $-0.18 |
| Q2 2024 | $1.7M | -$38.3M | $-0.41 |
| Q1 2024 | $1.4M | -$42.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NAMSW Capital Allocation
NAMSW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NewAmsterdam Pharma Co N.V. (CIK: 0001936258)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NAMSW
What is the AI rating for NAMSW?
NewAmsterdam Pharma Co N.V. (NAMSW) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAMSW's key strengths?
Claude: Strong cash position of $490M provides 3-4 year runway even at current burn rate. Minimal debt exposure with 0.00x debt-to-equity ratio and $85.9M total liabilities.
What are the risks of investing in NAMSW?
Claude: Revenue collapse of 50.6% YoY to $22.5M indicates severe product, market, or competitive challenges. Operating loss of $225.7M on minimal revenue demonstrates fundamental business model breakdown.
What is NAMSW's revenue and growth?
NewAmsterdam Pharma Co N.V. reported revenue of $22.5M.
Does NAMSW pay dividends?
NewAmsterdam Pharma Co N.V. does not currently pay dividends.
Where can I find NAMSW SEC filings?
Official SEC filings for NewAmsterdam Pharma Co N.V. (CIK: 0001936258) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAMSW's EPS?
NewAmsterdam Pharma Co N.V. has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NAMSW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NewAmsterdam Pharma Co N.V. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NAMSW stock overvalued or undervalued?
Valuation metrics for NAMSW: ROE of -29.8% (sector avg: 15%), net margin of -905.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NAMSW stock in 2026?
Our dual AI analysis gives NewAmsterdam Pharma Co N.V. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NAMSW's free cash flow?
NewAmsterdam Pharma Co N.V.'s operating cash flow is $-147.8M, with capital expenditures of $246.0K. FCF margin is -657.8%.
How does NAMSW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -905.7% (avg: 12%), ROE -29.8% (avg: 15%), current ratio 7.88 (avg: 2).